Clinical Research Directory
Browse clinical research sites, groups, and studies.
Theophylline for Treatment of Pseudohypoparathyroidism
Sponsor: Ashley Shoemaker
Summary
Pseudohypoparathyroidism is a genetic disorder with limited treatment options, characterized by early-onset obesity, short stature, hormone resistance and cognitive impairment. This phase 2 clinical trial will test the efficacy of theophylline, a phosphodiesterase inhibitor, in pseudohypoparathyroidism. We hypothesize that theophylline will cause weight loss, improve glucose tolerance and decrease hormone resistance in children and young adults.
Official title: Open-Label Extension Study of Theophylline for Treatment of Pseudohypoparathyroidism
Key Details
Gender
All
Age Range
2 Years - 99 Years
Study Type
INTERVENTIONAL
Enrollment
34
Start Date
2020-05-22
Completion Date
2026-12-31
Last Updated
2026-02-23
Healthy Volunteers
Yes
Conditions
Interventions
Theophylline ER
Oral theophylline
Locations (1)
Vanderbilt University Medical Center
Nashville, Tennessee, United States